Dallas-Fort Worth Metroplex
Have been a consistent top producer in Pharmaceutical Sales, Sales Management, and Coaching & Leadership development in progressively challenging roles. Dec 2024 earned a Regional Business Manager position with Axsome, a growing Neuroscience company with life changing products. Oct 2023 moved into a Renal Specialty sales Leadership building and leading an amazing team whose efforts grew to lead sales metrics to #1 in volume, #1 in breadth, and the #2 market share in the nation. Sept of 2019 moved into corporate taking a field role in Commercial Learning. Here I customize and facilitate learning experiences across a broad range of sales topics. In addition do special projects dealing with various development topics. Feb of 2014 the buyout of Amylin was completed with the 50% held by BMS going to AstraZeneca, remain commited to a strong group of talented reps in the diabetes field, selling both PO and injectables in new classes and with new injection devices. Earning circle of Excellence. Feb 2011, named Associate Director of District Sales with Amylin, earning a great opportunity to lead a talented group helping patients with diabetes. In 2006, I was recruited to lead the newly formed Medical Center Specialist division responsible for strategy, execution, development and talent assessment. Medical Center Specialists are a flexible sales force who sold in the hospitals, specialty clinics and high value targets from specialists to primary care. In addition I led the team in training and launch prep for three products while never losing focus on sales, demonstrating consistent high performance each year including President’s Club and three Special Achievement Awards. Prior to Joining Roche, I worked at Dillard’s Department Stores in progressively responsible roles leaving as Operation Manager, responsible for $28.5 million in sales and 193 employees including 9 managers.
Lead a team of Diabetes Specialist covering northern Half of Texas. Team was ranked 32/32 when I came aboard, by the end of 2011 improved quarterly ranking to 15/32. Current quarter ranking is #1. Currently selling Byetta (first GLP-1), Bydureon (first once weekly GLP-1) and Symlin (first and only synthetic amylin hormone). 2012- Won Launch Contest for March, April, May and June. 2011- Won "Shining Star" Award
Texas, Oklahoma, New Mexico, Arkansas and Tennessee Producer of strong sales results finishing #4 in 2010, #1 in 2009, #3 in 2008, #2 in 2007. Consistent top performance averaging 131.8% of performance target over 11 trimesters and quarters. Leading through competitive disadvantages grew Mycamine, an injectable anti-fungal, to top producing division with Market Share (58.6%) in the nation. Leader in sales for Boniva, a PO and IV for osteoporosis, in 2009 finishing at 13.1% growth on PO and 20.3% growth with IV. Initiated and led several regional based projects to influence sales and motivate employees beyond my division: Region Six Survey Project- Measured the motivation of entire region and pinpointed areas of improvement Metro Market Initiative- Data review, message development and resource optimization program for high value markets. Initiated first "Genentech Gives Back" volunteer project for Region Selected to be DM advisor serving on several committees from Compensation to new product training and Vice President's Advisory Board. Recruited as leader for Xolair Pilot Project, leading 6 reps from region in preparation to sell Xolair, a injectable biologic for asthma, by driving demand from Primary care offices. Led to 47 SMNs and 31 new patient starts and nationwide rollout timeline moved up. Leadership experience in broad points of care areas including; Hospital, Infusion Center and Clinic. Experience in therapeutic areas of Infectious Disease, Pulmonology, Transplant, Oncology, Rheumatology, Endocrinology, Nephrology, Internal Medicine, OB/GYN, Family Practice and Pharmacy. Extensive knowledge of Hospital Formulary Process, Managed Care Strategy and Buy and Bill process.
Dependable Top Producer averaging 146.2% of performance target over 11 trimesters. Leader of successes in areas of Hospital formulary additions, Managed Care Strategy and Buy and Bill. Progressively exceeded national sales of Boniva in 2006 with M/S of 16.2% vs. 12.5% for nation, in 2005 with M/S of 5.9% vs. 5.0% and product launch of 1.97% vs. 1.58%. Consistent high performance of Rocephin, an IV/IM antibiotic, 2005 M/S of 52.6% top 5% in nation, 2004 M/S of 51.6% market share, finished 2003 with 56.7% M/S. Extensive formulary additions for Kytril, an anti-emetic for PONV/CINV, led to 55% growth in 2003, 22.4% growth in 2004 and 44.3% growth in 2005.
Facilitated "Rx For Financial Health" program. Spearheaded transition of reps to newly created Alternate Market Rep position for Rocephin. Coached reps in order to develop and help them produce increased results for region.
Produced 125% of performance target over 9 trimesters. Extensive formulary experience with Parkland, Dallas VA, Children's Medical Center and UT Southwestern. Quote from DM when chosen to fill position: "If you can get this territory to perform above 90% it will be a success." Served as a trainer at home office for Rocephin, Tamiflu and Managed Care classes.